- Home
- CHI vs SEPN Comparison
CHI vs SEPN Comparison
Compare CHI & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- SEPN
- Stock Information
- Founded
- CHI 2002
- SEPN 2022
- Country
- CHI United States
- SEPN United States
- Employees
- CHI N/A
- SEPN N/A
- Industry
- CHI Investment Managers
- SEPN
- Sector
- CHI Finance
- SEPN
- Exchange
- CHI Nasdaq
- SEPN NYSE
- Market Cap
- CHI 879.5M
- SEPN 1.0B
- IPO Year
- CHI N/A
- SEPN 2024
- Fundamental
- Price
- CHI $12.04
- SEPN $21.79
- Analyst Decision
- CHI
- SEPN Strong Buy
- Analyst Count
- CHI 0
- SEPN 4
- Target Price
- CHI N/A
- SEPN $43.67
- AVG Volume (30 Days)
- CHI 186.2K
- SEPN 346.4K
- Earning Date
- CHI 01-01-0001
- SEPN 11-20-2024
- Dividend Yield
- CHI 9.90%
- SEPN N/A
- EPS Growth
- CHI N/A
- SEPN N/A
- EPS
- CHI N/A
- SEPN N/A
- Revenue
- CHI N/A
- SEPN $981,000.00
- Revenue This Year
- CHI N/A
- SEPN N/A
- Revenue Next Year
- CHI N/A
- SEPN N/A
- P/E Ratio
- CHI N/A
- SEPN N/A
- Revenue Growth
- CHI N/A
- SEPN N/A
- 52 Week Low
- CHI $9.70
- SEPN $18.62
- 52 Week High
- CHI $11.61
- SEPN $26.34
- Technical
- Relative Strength Index (RSI)
- CHI 59.96
- SEPN N/A
- Support Level
- CHI $11.60
- SEPN N/A
- Resistance Level
- CHI $12.08
- SEPN N/A
- Average True Range (ATR)
- CHI 0.17
- SEPN 0.00
- MACD
- CHI 0.03
- SEPN 0.00
- Stochastic Oscillator
- CHI 87.26
- SEPN 0.00
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.